New Study on Endometriosis Therapeutics Pipeline Assessment and Market Forecasts Now Available at MarketPublishers.com03 Oct 2011 • by Natalie Aster
LONDON – The total world endometriosis therapeutics market was estimated at $785m in 2010 and according to the professional market forecast it will witness growth by CAGR of 5.9% and reach $1,239m by 2018. This healthy growth rate is primarily attributed to the recently launched product, Visanne (dienogest) and the expected launch of the pipeline product, Elagolix (NBI-56418) in 2015 in the US and Europe.
Today’s market is considered to be underserved due to the lack of specific as well as non-invasive diagnostic techniques, alongside low disease awareness and the poor safety and moderate efficacy profiles of the current marketed therapies.
New market research report “Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018” developed by GlobalData features valuable review and analysis of the world endometriosis therapeutics market and identifies the key movements and trends shaping and driving it. The study covers insights on the current competitive landscape and the emerging players expected to shift the market positioning of the current market leaders. The report provides valuable information on the pipeline products within the global endometriosis therapeutics sector.
Title: Endometriosis Therapeutics- Pipeline Assessment and Market Forecasts to 2018
Published: September, 2011
Price: US$ 3,500
More studies on pipeline assessment and forecast are also available:
- Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Dysmenorrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2018
More new market reports by the publisher can be found at GlobalData page.
The Market Publishers, Ltd.
Mrs. Tanya Rezler
Tel: +44 208 123 2220
Fax: +44 207 900 3970